Company Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex.
The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
| Country | Israel |
| Founded | 2009 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Dror Ben-Asher |
Contact Details
Address: 21 Ha'arba'a Street Tel Aviv, L3 64739 Israel | |
| Phone | 972-3-541-3131 |
| Website | redhillbio.com |
Stock Details
| Ticker Symbol | RDHL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001553846 |
| CUSIP Number | 757468103 |
| ISIN Number | US7574682024 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dror Ben-Asher | Co-Founder, Chairman and Chief Executive Officer |
| Razi Ingber | Chief Financial Officer |
| Gilead Raday MPhil, MSc | Chief Operating Officer |
| Adi Frish | Chief Corporate and Business Development Officer |
| Rick D. Scruggs | Chief Commercial Officer, President of RedHill Biopharma Inc. and Director |
| Alexandra Okmian | Senior Business Development and Investor Relations Manager |
| Dr. Reza Fathi Ph.D. | Senior Vice President of Research and Development |
| Guy Goldberg J.D. | Chief Business Officer |
| Dr. June S. Almenoff FACP, M.D., Ph.D. | Chief Medical Officer |
| Patricia Anderson B.Sc. RAC | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 20, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 6, 2024 | 6-K | Report of foreign issuer |
| Jun 3, 2024 | 6-K | Report of foreign issuer |
| May 6, 2024 | 6-K | Report of foreign issuer |
| Apr 24, 2024 | 6-K | Report of foreign issuer |
| Apr 22, 2024 | EFFECT | Notice of Effectiveness |
| Apr 18, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 8, 2024 | 6-K | Report of foreign issuer |
| Apr 8, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 4, 2024 | 6-K | Report of foreign issuer |